35 completed, 7 recruiting, 4 unknown, 3 not yet recruiting. 17 Not applicable, 14 Phase 3, 10 Phase 2, 8 Phase 1, 3 Phase 4.
Follow Vasomotor Symptoms: new trials by email Literature Review of Vasomotor Symptoms trials Research Report on Vasomotor Symptoms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Hormone thERapy Effects on BRAin-HEART Health During the Menopausal Transition Transdermal estradiol, Standard of care - non hormonal - Menopause, Perimenopause | Phase 4 | Not yet recruiting | McGill University Health Centre/Research Institute of the McGill University Health Centre | 100 | 2026-11-01 | 2026-07-29 |
| Goji Berry and Vasomotor Symptoms Pilot Study Goji Berry Juice Powder, Goji Berry Powder - Vasomotor Symptoms | Not applicable | Not yet recruiting | University of California, Davis | 6 | 2026-10-25 | 2026-08-18 |
| Exercise Training Intensity and Nitrate Supplementation in Post-Menopausal Females on Hormone Therapy Moderate Intensity Exercise (MIE), High intensity exercise (HIE), Control (No exercise) - Postmenopausal Female Patients, Vasomotor Symptoms | Not applicable | Not yet recruiting | University of Virginia | 24 | 2026-10-15 | 2026-10-16 |
| A Trial on Fezolinetant for Vasomotor Symptoms in Men Receiving Androgen Deprivation Therapy (ADT) Fezolinetant, Placebo - Vasomotor Symptoms, Prostate Cancer | Phase 2 | Recruiting | Chinese University of Hong Kong | 54 | 2026-10-05 | 2026-10-07 |
| Reduce HEAT: A Randomized Trial of Wearable Thermal Devices for ADT-Induced Hot Flashes Embr Wave - Prostate Cancer, Hot Flashes | Not applicable | Recruiting | Dana-Farber Cancer Institute | 66 | 2026-10-01 | 2026-09-25 |
| Intra Ovarian Muse Cell Injection for Perimenopause Symptom Relief and Ovarian Function Restoration (MUSE-OVARY) Perimenopause, Perimenopause-Related Depression | Enrolling by invitation | Healing Hope International | 12 | 2026-06-01 | 2026-04-06 | |
| Proof-of-Concept Trial to Assess the Efficacy and Safety of Fezolinetant in Improving Vasomotor Symptoms in Men With Prostate Cancer Undergoing Androgen Deprivation Therapy fezolinetant - reference formulation, Placebo - Prostate Cancer, Prostate Cancer (Adenocarcinoma) | Phase 2 | Recruiting | Shehzad Basaria, M.D. | 60 | 2026-01-14 | 2026-08-17 |
| Men With Prostate Cancer: Optimizing Wellness by Enhanced Relief From Hot Flashes With Acupuncture Acupuncture, Lifestyle Management - Hot Flashes, Acupuncture Therapy | Not applicable | Recruiting | Inova Health Care Services | 24 | 2026-01-08 | 2026-02-04 |
| Efficacy of CL25216 on Vasomotor Symptoms in Women During Perimenopause CL25216, Placebo - Vasomotor Symptoms | Not applicable | Recruiting | ApexCPG LLC | 80 | 2025-11-24 | 2025-12-05 |
| A Study to Investigate Relative Bioavailability, Safety and Tolerability of Single- and Multiple-doses of Elinzanetant in Healthy Female Participants Treatment A, Treatment B, Treatment C - Vasomotor Symptoms | Phase 1 | Completed | Bayer | 18 | 2025-11-05 | 2026-01-27 |
| Safety and Efficacy of Asimadoline (TP0052) in Patients With Vasomotor Symptoms (VMS). Asimadoline - Vasomotor Symptoms | Phase 2 | Recruiting | Tioga Pharmaceuticals | 120 | 2025-08-13 | 2026-10-08 |
| Vasomotor Symptoms in Post-Hysterectomy Women With Ovarian Conservation Vasomotor Symptoms | Completed | Northwestern University | 20 | 2025-05-29 | 2026-04-27 | |
| JDS-HF3.0 Supplementation on Menopause Related Quality of Life Outcomes in Postmenopausal Women JDS-HF3.0, Placebo - Joint Discomfort, Joint Pain, Stiffness, Function | Not applicable | Recruiting | Bonafide Health | 250 | 2025-05-14 | 2025-11-20 |
| Nurse-led Primary Healthcare Intervention Model in Women's Health Management in Hong Kong Nurse-Led Risk-Based 5As Primary Healthcare Model, Minimal Intervention - Vasomotor Symptoms, Urinary Incontinence | Not applicable | Active not recruiting | The University of Hong Kong | 1728 | 2024-10-04 | 2026-04-29 |
| A Study to Find the Best Dose of HS-10384 to Treat Vasomotor Symptoms in Postmenopausal Women HS-10384 tablet Dose 1, HS-10384 tablet Dose 2, HS-10384-matched placebo tablets - Vasomotor Symptoms | Phase 2 | Unknown | Hansoh BioMedical R&D Company | 195 | 2024-05-30 | 2024-05-01 |
| Herbal Dietary Supplementation on Vasomotor Symptoms in Menopausal Women JDS-HF3.0 - Hot Flashes, Hot Flash | Not applicable | Completed | Bonafide Health | 112 | 2024-05-24 | 2026-02-12 |
| A Study to Assess Safety and Tolerability of GS1-144 in Healthy Volunteers GS1-144, Placebo - Vasomotor Symptoms, Adult Healthy Volunteers | Phase 1 | Completed | Changchun GeneScience Pharmaceutical Co., Ltd. | 86 | 2024-02-27 | 2025-02-17 |
| Study of HS-10384 in Participants of Chinese Postmenopausal Women HS-10384 tablets, HS-10384-matched placebo tablets - Vasomotor Symptoms | Phase 1 | Unknown | Hansoh BioMedical R&D Company | 48 | 2023-11-12 | 2024-03-13 |
| Herbal Nutraceutical Supplementation on Vasomotor Symptoms in Menopausal Women JDS-HF 3.0, Placebo - Vasomotor Symptoms, Postmenopausal Disorders | Not applicable | Completed | Bonafide Health | 74 | 2022-12-27 | 2024-06-26 |
| Study of DARE-HRT1 Over 12 Weeks in Healthy PostMenopausal Women IVR Dose 1, IVR Dose 2 - Vulvovaginal Atrophy, Vasomotor Symptoms | Phase 1 / Phase 2 | Completed | Daré Bioscience, Inc. | 21 | 2022-04-11 | 2024-10-31 |
Showing 20 of 56. Sign in to see all of them.
Hot Flashes (25) · Prostatic Neoplasms (4) · Breast Neoplasms (2) · Depressive Disorder, Major (2) · Multiple Endocrine Neoplasia Type 1 (2) · Adenocarcinoma (1) · Anxiety Disorders (1) · Arthralgia (1) · Colorectal Neoplasms (1) · Depression (1) · Diabetic Neuropathies (1) · Endocrine System Diseases (1) · Fibromyalgia (1) · Health Education (1) · Hypertension (1)
Pathological Conditions, Signs and Symptoms (26) · Signs and Symptoms (26) · Neoplasms (7) · Neoplasms by Site (7) · Genital Diseases (6) · Urogenital Diseases (6) · Male Urogenital Diseases (5) · Urogenital Neoplasms (5) · Genital Diseases, Male (4) · Genital Neoplasms, Male (4) · Mental Disorders (4) · Prostatic Diseases (4) · Behavior (3) · Musculoskeletal Diseases (3) · Nervous System Diseases (3)
Estradiol (3) · fezolinetant (3) · Acupuncture Therapy (2) · Bupivacaine (2) · Desvenlafaxine Succinate (2) · Estetrol (2) · Gabapentin (2) · Mirtazapine (2) · Sodium Chloride (2) · Yoga (2) · estradiol-drospirenone combination (2) · Autogenic Training (1) · Codeine (1) · Dehydroepiandrosterone (1) · Docosahexaenoic Acids (1)
Bayer (4) · Wyeth is now a wholly owned subsidiary of Pfizer (4) · Bonafide Health (3) · Northwestern University (3) · Pfizer (3) · Daré Bioscience, Inc. (2) · Estetra (2) · Fred Hutchinson Cancer Center (2) · Hansoh BioMedical R&D Company (2) · Merck Sharp & Dohme LLC (2) · Wake Forest University Health Sciences (2) · ApexCPG LLC (1) · Astellas Pharma Europe Ltd. (1) · Astellas Pharma Global Development, Inc. (1) · Aylin Güneş (1)
United States (30) · Canada (7) · Australia (3) · China (3) · Turkey (Türkiye) (3) · United Kingdom (3) · Czechia (2) · Germany (2) · Hong Kong (2) · Hungary (2) · Italy (2) · Mexico (2) · Poland (2) · Spain (2) · Argentina (1)
Andrea Z LaCroix, PhD (1) · Andrea Z. LaCroix, PhD (1) · Aylin Gunes, RN, PhD (1) · Barbara Sternfeld, PhD (1) · Bette Caan, DrPH (1) · Charles H. Tegeler, MD (1) · Charles W Hogue, MD (1) · Chi Fai NG, MD (1) · Daniel Sentana Lledo, MD (1)
PMID 23760428, PMID 26241433, PMID 29165623, PMID 30712391, PMID 32701665, PMID 41289787, PMID 18165395, PMID 21245182, PMID 22228322, PMID 22353950, PMID 22433978, PMID 22480818, PMID 23010882, PMID 23031421, PMID 23266839, PMID 23266840, PMID 23435022, PMID 23602542, PMID 23899828, PMID 23963307, PMID 23963309, PMID 23982113, PMID 24045673, PMID 26691637, PMID 27023860, PMID 35961801, PMID 36809193, PMID 37339390, PMID 37625088, PMID 37847872, PMID 39557487, PMID 41857501, PMID 42068869, PMID 42284819
U01AG032699 (2), 2004 (1), R21AT004234 (1), U01AG032656 (1), U01AG032669 (1), U01AG032682 (1)